Literature DB >> 2766296

In vitro clonogenic growth and metastatic potential of human operable breast cancer.

Y Nomura1, H Tashiro, K Hisamatsu.   

Abstract

In 254 patients with operable [International Union against Cancer (1972) Stages I, II, and III] breast cancer, the relations between in vitro clonogenic growth in soft agar of primary breast cancer tumors and their metastatic potential expressed by the relapse-free survivals (RFS) as well as overall survivals were studied. Sixty-four % (163 of 254) of cancers formed distinct colonies (30 or more colonies in a single dish, or 10 or more colonies in plural dishes). Other breast cancers (36%, 91 of 254) were designated to be negative for the clonogenicity. There was no correlation between the positive or negative clonogenicity and clinicopathological characteristics in breast cancer patients, including the age of patients, menopausal status, tumor size, T classification, International Union against Cancer stage, histological type (Japanese Breast Cancer Society), histologically proved axillary lymph node metastasis, and estrogen receptor (ER). At the time of median follow-up of 43 mo (range, 25 to 61 mo) after mastectomy, a recurrence of malignancy occurred in 19.0% (31 of 163) of the patients with positive clonogenic tumors, and in 8.8% (8 of 91) of those with negative clonogenic tumors (P = 0.03). There also was a significant difference (P less than 0.03 by log rank test, P less than 0.05 by generalized Wilcoxon test) in RFS curves between positive and negative clonogenicity groups. These differences in RFS were also noted in Stage II patients in favor of the negative colony formation group. In ER-negative cancer patients, the RFS of patients with positive clonogenic cancers was shown to be worse (P less than 0.03 by log rank test, P less than 0.05 by generalized Wilcoxon test) than patients with negative clonogenic cancers. There was no difference in RFS in ER-positive cancer patients. There was a trend (P = 0.09 by log rank test) of worse overall survival rate in patients with positive clonogenic growth. In a multivariate comparison using the principal component analysis composed of factors including positive node, T classification, histological type, age, ER, and colony formation, the clonogenicity showed a significant effect on the recurrence of malignancy and also on the survival of the patients after mastectomy. In conclusion, in vitro clonogenic growth of the primary tumor of breast cancer was shown to be one of the independent factors of metastatic potential in operable breast cancer patients after mastectomy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2766296

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  A role for collagen XXIII in cancer cell adhesion, anchorage-independence and metastasis.

Authors:  K A Spivey; I Chung; J Banyard; I Adini; H A Feldman; B R Zetter
Journal:  Oncogene       Date:  2011-10-03       Impact factor: 9.867

2.  Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs.

Authors:  G V Glinsky; V V Mossine; J E Price; D Bielenberg; V V Glinsky; H N Ananthaswamy; M S Feather
Journal:  Clin Exp Metastasis       Date:  1996-05       Impact factor: 5.150

3.  Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin.

Authors:  J Nip; H Shibata; D J Loskutoff; D A Cheresh; P Brodt
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

4.  Anchorage-independent cell growth signature identifies tumors with metastatic potential.

Authors:  S Mori; J T Chang; E R Andrechek; N Matsumura; T Baba; G Yao; J W Kim; M Gatza; S Murphy; J R Nevins
Journal:  Oncogene       Date:  2009-06-01       Impact factor: 9.867

5.  Chitosan gold nanoparticles induce cell death in HeLa and MCF-7 cells through reactive oxygen species production.

Authors:  Ana Carolina Martínez-Torres; Diana G Zarate-Triviño; Helen Yarimet Lorenzo-Anota; Andrea Ávila-Ávila; Carolina Rodríguez-Abrego; Cristina Rodríguez-Padilla
Journal:  Int J Nanomedicine       Date:  2018-05-31

6.  Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.

Authors:  Marie-Julie Nokin; Justine Bellier; Florence Durieux; Olivier Peulen; Gilles Rademaker; Maude Gabriel; Christine Monseur; Benoit Charloteaux; Lieven Verbeke; Steven van Laere; Patrick Roncarati; Michael Herfs; Charles Lambert; Jean Scheijen; Casper Schalkwijk; Alain Colige; Jo Caers; Philippe Delvenne; Andrei Turtoi; Vincent Castronovo; Akeila Bellahcène
Journal:  Breast Cancer Res       Date:  2019-01-23       Impact factor: 6.466

7.  Synergistic effect of cold atmospheric pressure plasma and free or liposomal doxorubicin on melanoma cells.

Authors:  Konstantina Pefani-Antimisiari; Dimitrios K Athanasopoulos; Antonia Marazioti; Kyriakos Sklias; Maria Rodi; Anne-Lise de Lastic; Athanasia Mouzaki; Panagiotis Svarnas; Sophia G Antimisiaris
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379

8.  The clonogenic growth of advanced breast tumour lesions adds no value to that of established clinical prognosticators for survival.

Authors:  V Hug; A Polyzos; S Tucker; H Thames
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

9.  Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.

Authors:  D J DeFriend; E Anderson; J Bell; D P Wilks; C M West; R E Mansel; A Howell
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

10.  Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells.

Authors:  Namrata Khurana; Partha K Chandra; Hogyoung Kim; Asim B Abdel-Mageed; Debasis Mondal; Suresh C Sikka
Journal:  Antioxidants (Basel)       Date:  2020-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.